FY2025 EPS Estimates for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Lifted by Capital One Financial

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Analysts at Capital One Financial increased their FY2025 earnings per share (EPS) estimates for Ironwood Pharmaceuticals in a research note issued on Wednesday, May 1st. Capital One Financial analyst T. Chiang now forecasts that the biotechnology company will earn $0.88 per share for the year, up from their previous forecast of $0.85. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.71 per share.

Several other equities research analysts have also issued reports on the company. Piper Sandler raised their target price on Ironwood Pharmaceuticals from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. StockNews.com cut shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, April 6th. Wells Fargo & Company decreased their price target on shares of Ironwood Pharmaceuticals from $20.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday, March 1st. Finally, Craig Hallum began coverage on shares of Ironwood Pharmaceuticals in a report on Wednesday, January 17th. They issued a “buy” rating and a $21.00 price target on the stock. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.80.

Ironwood Pharmaceuticals Trading Down 2.2 %

Shares of Ironwood Pharmaceuticals stock opened at $8.12 on Friday. The business’s fifty day simple moving average is $8.82 and its 200 day simple moving average is $10.61. Ironwood Pharmaceuticals has a 12 month low of $7.53 and a 12 month high of $15.70. The firm has a market capitalization of $1.27 billion, a P/E ratio of -1.25 and a beta of 0.57.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Walleye Capital LLC bought a new stake in Ironwood Pharmaceuticals during the third quarter valued at $1,608,000. Illinois Municipal Retirement Fund bought a new stake in shares of Ironwood Pharmaceuticals during the 3rd quarter valued at about $743,000. Jacobs Levy Equity Management Inc. purchased a new position in shares of Ironwood Pharmaceuticals during the third quarter worth about $22,903,000. Vanguard Group Inc. increased its position in shares of Ironwood Pharmaceuticals by 0.3% in the third quarter. Vanguard Group Inc. now owns 14,895,700 shares of the biotechnology company’s stock worth $143,446,000 after purchasing an additional 49,160 shares during the last quarter. Finally, Quantbot Technologies LP raised its stake in Ironwood Pharmaceuticals by 95.8% in the third quarter. Quantbot Technologies LP now owns 69,500 shares of the biotechnology company’s stock valued at $669,000 after purchasing an additional 34,000 shares in the last quarter.

Insider Activity at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, SVP Andrew Davis sold 9,846 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $15.24, for a total transaction of $150,053.04. Following the sale, the senior vice president now owns 208,324 shares in the company, valued at $3,174,857.76. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, Director Jon R. Duane acquired 6,920 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was bought at an average cost of $8.70 per share, for a total transaction of $60,204.00. Following the completion of the transaction, the director now owns 121,028 shares of the company’s stock, valued at $1,052,943.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Andrew Davis sold 9,846 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $15.24, for a total transaction of $150,053.04. Following the sale, the senior vice president now directly owns 208,324 shares in the company, valued at approximately $3,174,857.76. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 273,008 shares of company stock worth $4,160,642. 13.10% of the stock is owned by corporate insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.